A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

511

Participants

Timeline

Start Date

April 24, 2013

Primary Completion Date

December 16, 2016

Study Completion Date

December 16, 2016

Conditions
Alzheimer's Disease
Interventions
DRUG

Nilvadipine

8mg of Nilvadipine taken once a day at lunch time for 78 weeks

DRUG

Placebo

8mg Placebo tablet taken once a day at lunch time for 78 weeks

Trial Locations (23)

Unknown

Centre Hospitalier Universitaire d'Amiens (CHU Amiens), Amiens

Centre Hospitalier Universitaire de Bethune (CH Bethune), Béthune

Centre Hospitalier Universitaire de Caen (CHU Caen), Caen

Centre Hospitalier Universitaire de Calais (CHU Calais), Calais

Centre Hospitalier Universitaire de Lens (CHU Lens), Lens

Centre Hospitalier Regional et Universitaire de Lille (CHRU Lille), Lille

Centre Hospitalier Universitaire de Saint Philibert (GHICL), Lille

University of Ulm, Ulm

"G. Papanicolaou Hospital", Athens

"G.Papageorgiou Hospital", Athens

AXEPA Hospital, Athens

Szeged University, Szeged

University College Cork, Cork

St James Hospital, Dublin

Hospital of Brescia, Brescia

Hospital Castellanza, Castellanza

Hospital of Genoa, Genoa

Hospital of Milan, Milan

Hospital of Arnhem, Arnhem

Hospital of Maastricht, Maastricht

Hospital of Nijmegen, Nijmegen

Gothenburg Univeristy, Gothenburg

Kings College London, London

All Listed Sponsors
collaborator

University of Dublin, Trinity College

OTHER

collaborator

Molecular Medicine Ireland LBG

UNKNOWN

collaborator

Alzheimer Europe

OTHER

collaborator

Archer Pharmaceuticals, Inc.

INDUSTRY

collaborator

E-Search Limited

UNKNOWN

collaborator

University College Dublin

OTHER

collaborator

King's College London

OTHER

collaborator

Istituto Di Ricerche Farmacologiche Mario Negri

OTHER

collaborator

University Hospital, Lille

OTHER

collaborator

University of Ulm

OTHER

collaborator

Szeged University

OTHER

collaborator

Göteborg University

OTHER

collaborator

University College Cork

OTHER

collaborator

Aristotle University Of Thessaloniki

OTHER

collaborator

Stichting Katholieke Universiteit

OTHER

lead

Prof Brian Lawlor

OTHER